Aripiprazole

Aripiprazole

SCHEMBL2080933

CO.O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2HTR1AHTR2A

The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 20/20 0.95
HTR1A known ✓ P08908 3/20 0.95
HTR2A known ✓ P28223 3/20 0.95
DRD3 P35462 7/20 0.95
DRD4 P21917 6/20 0.95
HTR2B P41595 3/20 0.95
DRD1 P21728 2/20 0.95
DRD5 P21918 2/20 0.95
HTR2C P28335 2/20 0.95
HTR7 P34969 2/20 0.95
HTR6 P50406 2/20 0.95
HTR3E A5X5Y0 1/20 0.95
MEN1 O00255 1/20 0.95
MLNR O43193 1/20 0.95
HTR3B O95264 1/20 0.95
ABCB11 O95342 1/20 0.95
ESR1 P03372 1/20 0.95
PGR P06401 1/20 0.95
ADRB2 P07550 1/20 0.95
CHRM2 P08172 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aripiprazole SCHEMBL8255 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL29356997 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL29438823 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL29475638 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL29475637 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL982189 0.97 DRD2 (1.00) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL6023131 0.97 DRD2 (0.92) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL2235757 0.97 DRD2 (0.92) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL7097505 0.96 DRD2 (0.98) DRD2DRD3DRD4HTR1AHTR2A
Aripiprazole SCHEMBL30958765 0.96 DRD2 (0.98) DRD2DRD3DRD4HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093217-B1 Process for preparing Form X of aripiprazole SANDOZ AG (CH) 2014-03-12 EP claimed
CN-101370780-B polymorphic forms of aripiprazole SANDOZ AG 2012-05-16 CN claimed
US-8008490-B2 novel polymorphic forms of aripiprazole in the treatment of schizophrenia; properties suitable for pharmaceutical processing on a commercial scale SANDOZ AG (CH) 2011-08-30 US claimed
EP-2093217-A1 Polymorph and solvates of aripiprazole Sandoz AG (CH) 2009-08-26 EP claimed
US-20090198059-A1 Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts SATYANARAYANA CHAVA 2009-08-06 US claimed
CN-101370780-A Organic compounds SANDOZ AG (CH) 2009-02-18 CN claimed
US-20080132518-A1 Organic Compounds SANDOZ AG (CH) 2008-06-05 US claimed
EP-1844016-A1 POLYMORPH AND SOLVATES OF ARIPIPRAZOLE Sandoz AG (CH) 2007-10-17 EP claimed
EP-1797039-A1 PROCESS FOR THE PREPARATION OF POLYMORPHS, SOLVATES OF ARIPIPRAZOLE USING ARIPIPRAZOLE ACID SALTS Matrix Laboratories Ltd (IN) 2007-06-20 EP claimed
WO-2006079548-A1 ORGANIC COMPOUNDS SANDOZ AG (CH) 2006-08-03 WO claimed
EP-1686117-A1 Polymorph and solvates of aripiprazole Sandoz AG (CH) 2006-08-02 EP claimed
WO-2006030446-A1 PROCESS FOR THE PREPARATION OF POLYMORPHS, SOLVATES OF ARIPIPRAZOLE USING ARIPIPRAZOLE ACID SALTS MATRIX LABORATORIES LTD (IN) 2006-03-23 WO claimed
CN-1676517-A Aripiprazole crystal form DEZHONG WANQUAN MEDICINE TECHN (CN) 2005-10-05 CN claimed
CN-103172563-B Industrialized preparation of small-particle-size crystal-form I aripiprazole JEWIM PHARMACEUTICAL RES INST CO LTD 2015-03-25 CN disclosed
EP-2093217-B1 Process for preparing Form X of aripiprazole SANDOZ AG (CH) 2014-03-12 EP disclosed
CN-103172563-A Industrialized preparation of small-particle-size crystal-form I aripiprazole JEWIM BEIJING PHARMACEUTICAL INST CO LTD 2013-06-26 CN disclosed
EP-1686117-A1 Polymorph and solvates of aripiprazole Sandoz AG (CH) 2006-08-02 EP disclosed
US-20060142299-A1 Crystalline aripiprazole solvates SYNTHON BV (NL) 2006-06-29 US disclosed
WO-2006053780-A1 CRYSTALLINE ARIPIPRAZOLE SOLVATES SYNTHON B.V. (NL) 2006-05-26 WO disclosed
WO-2006030446-A1 PROCESS FOR THE PREPARATION OF POLYMORPHS, SOLVATES OF ARIPIPRAZOLE USING ARIPIPRAZOLE ACID SALTS MATRIX LABORATORIES LTD (IN) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142299-A1 Crystalline aripiprazole solvates ADH1A, ADH5, ADH1C DRD2 760/4885HTR1A 148/4885HTR2A 146/4885
US-20090198059-A1 Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts CYP3A4, CYP3A5, CYP3A43 DRD2 1058/4885HTR1A 291/4885HTR2A 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.